Top

BMC Psychiatry

Published in:

Open Access 01-12-2015 | Study protocol

Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study

Authors: Inge Joa, Jens Gisselgård, Kolbjørn Brønnick, Thomas McGlashan, Jan Olav Johannessen

Published in: BMC Psychiatry | Issue 1/2015

Abstract

Background

Evidence has been accumulating that it may be possible to achieve prevention in psychotic disorders. The aim of the Prevention Of Psychosis (POP) study is to reduce the annual incidence of psychotic disorders in a catchment area population through detection and intervention in the prodromal phase of disorder. Prodromal patients will be recruited through information campaigns modelled on the Scandinavian early Treatment and Intervention in Psychosis (TIPS) study and assessed by low-threshold detection teams.

Methods/Design

The study will use a parallel control design comparing the incidence of first episode psychotic disorders between two Norwegian catchment areas with prodromal detection and treatment (Stavanger and Fonna) with two catchment areas without a prodromal intervention program (Bergen and Østfold). The primary aim of the current study is to test the effect of a Prodromal Detection and Treatment program at the health care systems level. The study will investigate: 1) If the combination of information campaigns and detection teams modelled will help in identifying individuals (age 13–65, fulfilling study inclusion criteria) at high risk of developing psychosis early, and 2) If a graded, multi-modal treatment program will reduce rates of conversion compared to the rates seen in follow-along assessments.

Discussion

Positive results could potentially revolutionize therapy by treating risk earlier rather than disorder later and could open a new era of early detection and intervention in psychosis. Negative results will suggest that the potential for psychosis is determined early in life and that research should focus more on genetically linked neurodevelopmental processes.

If we can identify people about to become psychotic with high accuracy, we can track them to understand more about how psychosis unfolds. Appropriate intervention at this stage could also prevent or delay the onset of psychosis and/or subsequent deterioration, i.e., social and instrumental disability, suicide, aggressive behavior, affective- and cognitive deficits.

Trial registration

Current Controlled Trials ISRCTN20328848. Registered 02 November 2014.

Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61(2):143–50.PubMed

Johannessen JO, McGlashan TH, Larsen TK, Horneland M, Joa I, Mardal S, et al. Early detection strategies for untreated first-episode psychosis. Schizophr Res. 2001;51(1):39–46.PubMed

Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169(4):374–80.PubMed

Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, et al. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014;8(2):153–82.PubMedPubMedCentral

Reay R, Mitford E, McCabe K, Paxton R, Turkington D. Incidence and diagnostic diversity in first-episode psychosis. Acta Psychiatr Scand. 2010;121(4):315–9.PubMed

Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry. 2006;163(5):800–4.PubMed

Larsen TK, Melle I, Auestad B, Haahr U, Joa I, Johannessen JO, et al. Early detection of psychosis: positive effects on 5-year outcome. Psychol Med. 2011;41(7):1461–9.PubMed

Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65(6):634–40.PubMed

Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220–9.PubMed

10.

Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353–70.PubMed

11.

Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15.PubMed

12.

McFarlane WR, Cook WL, Downing D, Verdi MB, Woodberry KA, Ruff A. Portland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosis. Psychiatr Serv. 2010;61(5):512–5.PubMedPubMedCentral

13.

Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172(33):14–20.PubMed

14.

Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863–5.PubMed

15.

Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158–64.PubMed

16.

Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophr Res. 2004;71(2–3):227–37.PubMed

17.

Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005;39(11–12):964–71.PubMed

18.

Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28–37.PubMedPubMedCentral

19.

Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168(8):800–5.PubMedPubMedCentral

20.

Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33(3):673–81.PubMedPubMedCentral

21.

Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry. 2011;72(4):430–40.PubMed

22.

Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res. 2011;132(1):8–17.PubMed

23.

Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346:f185.PubMedPubMedCentral

24.

Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291–7.PubMed

25.

Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54–61.PubMed

26.

Morrison AP, Turkington D, Wardle M, Spencer H, Barratt S, Dudley R, et al. A preliminary exploration of predictors of outcome and cognitive mechanisms of change in cognitive behaviour therapy for psychosis in people not taking antipsychotic medication. Behav Res Ther. 2012;50(2):163–7.PubMed

27.

van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38(6):1180–8.PubMedPubMedCentral

28.

Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry. 2009;43(9):818–29.PubMed

29.

McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921–8.PubMed

30.

McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790–9.PubMed

31.

Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200(1):22–9.PubMed

32.

Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83(1):29–40.PubMed

33.

Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54.PubMed

34.

Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl. 2007;51:s88–95.PubMed

35.

McFarlane E, Dodge RA, Burrell L, Crowne S, Cheng TL, Duggan AK. The importance of early parenting in at-risk families and children’s social-emotional adaptation to school. Acad Pediatr. 2010;10(5):330–7.PubMedPubMedCentral

36.

Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69(6):562–71.PubMed

37.

Giuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des. 2012;18(4):399–415.PubMed

38.

Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578–88.PubMedPubMedCentral

39.

Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry. 2008;165(5):579–87.PubMed

40.

Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res. 2011;132(1):1–7.PubMed

41.

McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci. 2008;29(2):91–8.PubMed

42.

Phillips LJ, Velakoulis D, Pantelis C, Wood S, Yuen HP, Yung AR, et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res. 2002;58(2–3):145–58.PubMed

43.

Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006;63(2):139–49.PubMed

44.

Yucel M, Wood SJ, Phillips LJ, Stuart GW, Smith DJ, Yung A, et al. Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. Br J Psychiatry. 2003;182:518–24.PubMed

45.

Mechelli A, Riecher-Rossler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 2011;68(5):489–95.PubMed

46.

Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull. 2012;38(6):1297–307.PubMed

47.

Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, et al. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull. 2008;34(3):466–72.PubMed

48.

Loewy RL, Pearson R, Vinogradov S, Bearden CE, Cannon TD. Psychosis risk screening with the Prodromal Questionnaire–brief version (PQ-B). Schizophr Res. 2011;129(1):42–6.PubMedPubMedCentral

49.

Morrison AP, Stewart SL, French P, Bentall RP, Birchwood M, Byrne R, et al. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Interv Psychiatry. 2011;5(1):24–32.PubMed

50.

O’Brien MP, Zinberg JL, Ho L, Rudd A, Kopelowicz A, Daley M, et al. Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr Res. 2009;107(2–3):198–205.PubMed

51.

Miklowitz DJ, O’Brien M, Schlosser DA, Zinberg JL, De Silva S, George EL, et al. Clinician’s treatment manual for family-Focused Therapy for Prodromal Youth (FFT-PY). 2010.

52.

First MSR, Gibbon M, Williams J. Structured clinical interview for DSM-IV Axis I Disorders-Patient Edition (SCID I/P, Version 2.0). New York: New York State Psychiatric Institute, Biometrics Research Dept; 1995.

53.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.PubMed

54.

Schlagenhauf F, Wustenberg T, Schmack K, Dinges M, Wrase J, Koslowski M, et al. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol. 2008;18(8):589–99.PubMed

55.

Schlagenhauf F, Dinges M, Beck A, Wustenberg T, Friedel E, Dembler T, et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res. 2010;118(1–3):189–200.PubMed

56.

Deserno L, Sterzer P, Wustenberg T, Heinz A, Schlagenhauf F. Reduced prefrontal-parietal effective connectivity and working memory deficits in schizophrenia. J Neurosci. 2012;32(1):12–20.PubMed

57.

Hugdahl K, Andersson L. The “forced-attention paradigm” in dichotic listening to CV-syllables: a comparison between adults and children. Cortex. 1986;22(3):417–32.PubMed

58.

Hugdahl K, Rund BR, Lund A, Asbjornsen A, Egeland J, Landro NI, et al. Attentional and executive dysfunctions in schizophrenia and depression: evidence from dichotic listening performance. Biol Psychiatry. 2003;53(7):609–16.PubMed

59.

Kompus K, Specht K, Ersland L, Juvodden HT, van Wageningen H, Hugdahl K, et al. A forced-attention dichotic listening fMRI study on 113 subjects. Brain Lang. 2012;121(3):240–7.PubMed

60.

Hiscock M, Stewart C. The effect of asymmetrically focused attention upon subsequent ear differences in dichotic listening. Neuropsychologia. 1984;22(3):337–51.PubMed

61.

Westerhausen R, Woerner W, Kreuder F, Schweiger E, Hugdahl K, Wittling W. The role of the corpus callosum in dichotic listening: a combined morphological and diffusion tensor imaging study. Neuropsychology. 2006;20(3):272–9.PubMed

62.

van den Noort M, Specht K, Rimol LM, Ersland L, Hugdahl K. A new verbal reports fMRI dichotic listening paradigm for studies of hemispheric asymmetry. Neuroimage. 2008;40(2):902–11.PubMed

Title: Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study
Authors: Inge Joa
Jens Gisselgård
Kolbjørn Brønnick
Thomas McGlashan
Jan Olav Johannessen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2015
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-015-0470-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study

Abstract

Background

Methods/Design

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods/Design

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2015

Reliability and validity of ADHD diagnostic criteria in the Assessment System for Individuals with ADHD (ASIA): a Japanese semi-structured diagnostic interview

Type specific Real time PCR for detection of human herpes virus 6 in schizophrenia and bipolar patients: a case control study

Immediate effects of the Fukushima nuclear power plant disaster on depressive symptoms among mothers with infants: a prefectural-wide cross-sectional study from the Fukushima Health Management Survey

Cost effectiveness of interpersonal community psychiatric treatment for people with long-term severe non-psychotic mental disorders: protocol of a multi-centre randomized controlled trial

A pilot randomized controlled trial of a stepped care intervention package for depression in primary care in Nigeria

The effect of the mental health first-aid training course offered employees in Denmark: study protocol for a randomized waitlist-controlled superiority trial mixed with a qualitative study